Phoenix Asia Holdings Ltd operates its business through its indirectly wholly-owned Operating Subsidiary. It is engaged in substructure works, such as site formation, ground investigation, and foundation works, in Hong Kong. To a lesser extent, the company also provides other construction services such as structural steelworks.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$15.30 – $17.93
Volume2,214
Market cap$352M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for PHOE.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for PHOE.
Recent news
Company coverage with links to the original publishers.
Phoenix Asia Holdings announced a $1 billion stock acquisition agreement to acquire clinical-stage pharmaceutical firm ACEA Pharma Inc., marking a strategic pivot from construction into oncology and autoimmune drug development. The stock surged 47.43% in after-hours trading to $28.10, though it closed the regular session down 33.36% at $19.06. The deal requires Hart-Scott-Rodino antitrust clearance and Nasdaq review, with closing expected in Q2 2026.
Phoenix Asia Holdings (NASDAQ: PHOE) stock gained 0.19% on Thursday following the announcement of a $1 billion acquisition agreement to purchase 100% of ACEA Pharma, Inc. through the issuance of 100 million shares at $10 each. The deal is expected to close by end of Q2 2026 and marks the company's expansion into the pharmaceutical sector while maintaining its core construction operations in Hong Kong.
Scilex Holding Company announced that its subsidiaries ACEA Therapeutics and ACEA Pharma entered into a definitive agreement to sell 100% of ACEA Pharma's equity to Phoenix Asia Holdings Limited for $1 billion in newly-issued shares. Upon closing, Phoenix will be renamed ACEA Pharma and listed on Nasdaq, with ACEA Thera retaining approximately 82% ownership. The transaction is expected to close by end of Q2 2026, subject to regulatory and stock exchange approvals.
Scilex Holding Company's subsidiaries ACEA Therapeutics and ACEA Pharma have entered into a definitive stock acquisition agreement with Phoenix Asia Holdings Limited. Under the deal, ACEA will transfer 100% of ACEA Pharma's equity to Phoenix in exchange for 100 million newly-issued ordinary shares at $10 per share, valuing the transaction at $1 billion. Upon closing, Phoenix will be renamed ACEA Pharma, Inc. and its stock is expected to list on Nasdaq. The transaction is expected to close by end of Q2 2026, subject to regulatory approvals.
The 33rd China Cycle Expo 2025 opened in Shanghai, showcasing the latest innovations and trends in the global cycling industry. The event featured leading brands, new technologies, and a focus on industry transformation and upgrading.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.